Dufresne Simon F, Shahmirzadi Mohammadreza R, Deotare Uday, Kabbani Dima, Husain Shahid, Rotstein Coleman, Hosseini-Moghaddam Seyed M
Division of Infectious Diseases and Medical Microbiology, Department of Medicine, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC H1T 2M4, Canada.
Division of Infectious Diseases, Department of Medicine, London Health Sciences Centre, Western University, London, ON N6A 3K7, Canada.
Curr Oncol. 2025 Sep 19;32(9):525. doi: 10.3390/curroncol32090525.
Measles exposures have historically been rare since the introduction of routine vaccination programs, resulting in a lack of attention from cancer patients, hematopoietic stem cell transplant (HCT) recipients, patients receiving cellular therapy (CT) and their healthcare providers. It is essential to acknowledge the importance of vigilance in these situations. Measles herd immunity has declined significantly in North America due to rising vaccine hesitancy, resulting in outbreaks. Measles can result in severe outcomes, and its reemergence has raised alarm among patients and healthcare professionals caring for HCT/CT recipients. Patients with severe immunocompromising conditions cannot receive live-attenuated vaccines, such as the measles vaccine. The lack of data on measles prevention in this vulnerable group presents significant clinical challenges. In response, Cell Therapy Transplant Canada (CTTC) Infectious Diseases Working Committee has developed a set of frequently asked questions to provide expert guidance to HCT and CT recipients, acknowledging the limited evidence base.
自实施常规疫苗接种计划以来，麻疹暴露情况在历史上一直很少见，导致癌症患者、造血干细胞移植（HCT）受者、接受细胞疗法（CT）的患者及其医疗服务提供者对此缺乏关注。认识到在这些情况下保持警惕的重要性至关重要。由于疫苗犹豫情绪上升，北美地区的麻疹群体免疫力显著下降，导致了疫情爆发。麻疹可能会导致严重后果，其再次出现引起了照顾HCT/CT受者的患者和医疗专业人员的警觉。患有严重免疫功能低下疾病的患者不能接种减毒活疫苗，如麻疹疫苗。该弱势群体中缺乏麻疹预防数据带来了重大临床挑战。作为回应，加拿大细胞疗法移植协会（CTTC）传染病工作委员会制定了一套常见问题解答，以在证据基础有限的情况下为HCT和CT受者提供专家指导。
